Therapeutic vulnerability in a medulloblastoma subgroup
Medulloblastoma (MB) is the most common pediatric brain tumor. Despite significant clinical progress over the last few decades, this disease is still aggressive. Identifying new treatments is an important clinical question.
Based on epigenomic and transcriptomic profiles 4 distinct MB subgroups have been identified.
To better understand their biology, Forget et al associated a proteomics and phosphoproteomics analysis with existing data. Based on this integrative proteogenomic approach, the team were able to identify new therapeutic targets.